---
title: "Vera Therapeutics (VERA) Gets a Buy from LifeSci Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285608009.md"
description: "LifeSci Capital analyst Rami Katkhuda has maintained a Buy rating on Vera Therapeutics (VERA) with a price target of $90.00. The analyst focuses on the Healthcare sector and has an average return of 31.9% with a 54.36% success rate on stock recommendations. Vera Therapeutics holds a Strong Buy consensus among analysts, with a price target consensus of $83.50."
datetime: "2026-05-07T19:55:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285608009.md)
  - [en](https://longbridge.com/en/news/285608009.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285608009.md)
---

# Vera Therapeutics (VERA) Gets a Buy from LifeSci Capital

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Vera Therapeutics, with a price target of $90.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Viridian Therapeutics, and Disc Medicine. According to TipRanks, Katkhuda has an average return of 31.9% and a 54.36% success rate on recommended stocks.

Vera Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $83.50.

### Related Stocks

- [VERA.US](https://longbridge.com/en/quote/VERA.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md)